Literature DB >> 12763554

Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996-2000).

Geoffrey T Lamke1, Rachel D Allen, William D Edwards, Henry D Tazelaar, Gordon K Danielson.   

Abstract

BACKGROUND: No large surgical series have qualitatively examined all histopathologic features of hypertrophic cardiomyopathy (HCM).
METHODS: Medical records and microscopic slides were reviewed from 204 patients undergoing septal myectomy for HCM at Mayo Clinic Rochester.
RESULTS: The 108 females and 96 males (1-86 years old; mean, 48) included 133 patients <60 years old (Group 1) and 71 patients > or =60 years (Group 2). Clinical features more prevalent in Group 2 than in Group 1 included female gender (68% vs. 45%; P=.003), aortic valve disease (31% vs. 12%; P=.01) and severe coronary atherosclerosis (43% vs. 9%; P=.001). Overall, microscopic abnormalities included myocyte hypertrophy (100%), endocardial (96%) and myocardial (93%) fibrosis, myocyte disarray (79%) and vacuolization (60%), endocardial inflammation (48%), arterial thickening (46%), dilated venules (28%), arterial dysplasia (16%), left bundle branch tissue (12%), infarction (2%), endocardial (1%) and myocardial (<1%) calcium, and amyloid (1%; senile type in all three). Lesions more prevalent in Group 1 than Group 2 were vacuolization (68% vs. 45%; P=.002), disarray (87% vs. 65%; P=.0003) and dilated venules (33% vs. 18%; P=.02). In contrast, lesions more frequent in Group 2 than in Group 1 included left bundle branch (20% vs. 8%; P=.02) and amyloid and endocardial calcium (4% vs. 0%; P=.04, each).
CONCLUSIONS: Among patients undergoing septal myectomy for HCM, 53% were women and 35% were >/=60 years old. The most common microscopic features were hypertrophy, disarray, fibrosis, inflammation and vascular alterations. Disarray cannot be used as a morphologic hallmark for HCM in small surgical myectomy specimens because it was absent in 21% of the patients. Because amyloid unexpectedly affected three elderly patients, routine amyloid staining is recommended for patients >/=65 years old.

Entities:  

Mesh:

Year:  2003        PMID: 12763554     DOI: 10.1016/s1054-8807(03)00036-x

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  22 in total

1.  Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: a PET and MRI study.

Authors:  Paul Knaapen; Willem G van Dockum; Marco J W Götte; Kimiko A Broeze; Joost P A Kuijer; Jaco J M Zwanenburg; J Tim Marcus; Wouter E M Kok; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 2.  Hypertrophic cardiomyopathy: genetics and clinical perspectives.

Authors:  Cordula Maria Wolf
Journal:  Cardiovasc Diagn Ther       Date:  2019-10

3.  Delayed hyperenhancement in magnetic resonance imaging of left ventricular hypertrophy caused by aortic stenosis and hypertrophic cardiomyopathy: visualisation of focal fibrosis.

Authors:  K Debl; B Djavidani; S Buchner; C Lipke; W Nitz; S Feuerbach; G Riegger; A Luchner
Journal:  Heart       Date:  2006-04-10       Impact factor: 5.994

Review 4.  The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice.

Authors:  Iacopo Olivotto; Francesca Girolami; Stefano Nistri; Alessandra Rossi; Luigi Rega; Francesca Garbini; Camilla Grifoni; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-27       Impact factor: 4.132

5.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Lu Fang; Andris H Ellims; Anna L Beale; Andrew J Taylor; Andrew Murphy; Anthony M Dart
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

6.  T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy.

Authors:  Christopher T Sibley; Radwa A Noureldin; Neville Gai; Marcelo Souto Nacif; Songtao Liu; Evrim B Turkbey; James O Mudd; Rob J van der Geest; João A C Lima; Marc K Halushka; David A Bluemke
Journal:  Radiology       Date:  2012-10-22       Impact factor: 11.105

Review 7.  Distinguishing ventricular septal bulge versus hypertrophic cardiomyopathy in the elderly.

Authors:  Marco Canepa; Iraklis Pozios; Pier Filippo Vianello; Pietro Ameri; Claudio Brunelli; Luigi Ferrucci; Theodore P Abraham
Journal:  Heart       Date:  2016-04-27       Impact factor: 5.994

8.  Is there a role for cardiac positron emission tomography in hypertrophic cardiomyopathy?

Authors:  Paco E Bravo
Journal:  J Nucl Cardiol       Date:  2018-05-14       Impact factor: 5.952

9.  Histologic characterization of hypertrophic cardiomyopathy with and without myofilament mutations.

Authors:  Christopher J McLeod; J Martijn Bos; Jeanne L Theis; William D Edwards; Bernard J Gersh; Steve R Ommen; Michael J Ackerman
Journal:  Am Heart J       Date:  2009-10-03       Impact factor: 4.749

Review 10.  The "1st septal unit" in hypertrophic obstructive cardiomyopathy: a newly recognized anatomo-functional entity, identified during recent alcohol septal ablation experience.

Authors:  Paolo Angelini
Journal:  Tex Heart Inst J       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.